The Microscopy and Cell Analysis Core is fully equipped and expertly staffed to perform specimen preparation, light and electron microscopy, photography, digital imaging, and multi-parameter Flow and Cell Sorting services to Mayo Clinic Cancer Center investigators from both clinical and basic science laboratories. The facility also performs X-ray probe microanalysis, immuno-gold labeling, 3-D EM reconstruction from serial-sectioned specimens, and high-resolution reconstruction using image averaging of negative stained and cryo-tomography imaged specimens. Instrumentation and expertise are also supported in the core for high-end optical, two-photon, super-resolution, laser confocal, TIRF, ratio imaging, and other optical methods, as well as Flow Cytometry and Live Cell Sorting technologies and analysis. Additionally, the core staff (23 FTEs) and the core director are available for the development and/or implementation of new microscopy techniques and for testing and evaluation of instrumentation that would be of value to individual Mayo Cancer Center investigators and the greater research community. During the last budget year, the Microscopy and Cell Analysis Shared Resource has been widely utilized by each of the Mayo Cancer Center Programs. During the past 12 months, the facility served over 100 Mayo Cancer Center investigators processing 1000-plus specimens for electron microscopy, and logging 5,000 hours of Optical Microscopy and over 5000 hours of Flow Analysis and Cell Sorting. Because of the large expense for purchase and maintenance of high-end optical and electron microscopes, and the expertise required for their productive use, most investigators and their research laboratories find the Microscopy and Cell Analysis Core services to be the most economical, practical, and up-to-date means to achieve their sophisticated microscopy and cell sorting and analysis research needs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682943
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$280,370
Indirect Cost
$104,183
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227

Showing the most recent 10 out of 1129 publications